Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 CountriesBioDrugs, 2024, v.38 no.1, 133-144
Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey StudyBioDrugs, 2024, v.38 no.2, 301-311